Skip to main content Back to Top
Advertisement

10/16/2019

Amphetamine Mixed Salts, Immediate-Release Tablets

Products Affected - Description

    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 10 mg, bottle, 100 count, NDC 00406-8892-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 15 mg, bottle, 100 count, NDC 00406-8885-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 20 mg, bottle, 100 count, NDC 00406-8893-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 30 mg, bottle, 100 count, NDC 00406-8894-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 5 mg, bottle, 100 count, NDC 00406-8891-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 12.5 mg, bottle, 100 count, NDC 00378-4544-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 15 mg, bottle, 100 count, NDC 00378-4545-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 20 mg, bottle, 100 count, NDC 00378-4546-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 30 mg, bottle, 100 count, NDC 00378-4547-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 5 mg, bottle, 100 count, NDC 00378-4541-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 7.5 mg, bottle, 100 count, NDC 00378-4542-01
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 10 mg, bottle, 100 count, NDC 57664-0643-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 12.5 mg, bottle, 100 count, NDC 57664-0644-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 15 mg, bottle, 100 count, NDC 57664-0645-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 20 mg, bottle, 100 count, NDC 57664-0646-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 30 mg, bottle, 100 count, NDC 57664-0647-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 5 mg, bottle, 100 count, NDC 57664-0641-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 7.5 mg, bottle, 100 count, NDC 57664-0642-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Teva, 10 mg, bottle, 100 count, NDC 00555-0972-02
    • Amphetamine mixed salts immediate release tablet, Teva, 15 mg, bottle, 100 count, NDC 00555-0777-02
    • Amphetamine mixed salts immediate release tablet, Teva, 20 mg, bottle, 100 count, NDC 00555-0973-02
    • Amphetamine mixed salts immediate release tablet, Teva, 7.5 mg, bottle, 100 count, NDC 00555-0775-02
    • Amphetamine mixed salts immediate release tablet, Zydus, 10 mg, bottle, 100 count, NDC 68382-0952-01

Reason for the Shortage

    • Aurobindo refuses to provide updated availability information.
    • Mallinckrodt has amphetamine mixed salts on allocation due to increased demand.
    • Sun Pharma discontinued amphetamine mixed salts in 2019.
    • Teva did not provide a reason for the shortage.
    • Zydus has amphetamine mixed salts available.
    • Mylan did not provide a reason for the shortage

Available Products

    • Adderall immediate release tablet, Teva, 10 mg, bottle, 100 count, NDC 57844-0110-01
    • Adderall immediate release tablet, Teva, 12.5 mg, bottle, 100 count, NDC 57844-0112-01
    • Adderall immediate release tablet, Teva, 15 mg, bottle, 100 count, NDC 57844-0115-01
    • Adderall immediate release tablet, Teva, 20 mg, bottle, 100 count, NDC 57844-0120-01
    • Adderall immediate release tablet, Teva, 30 mg, bottle, 100 count, NDC 57844-0130-01
    • Adderall immediate release tablet, Teva, 5 mg, bottle, 100 count, NDC 57844-0105-01
    • Adderall immediate release tablet, Teva, 7.5 mg, bottle, 100 count, NDC 57844-0117-01
    • Amphetamine mixed salts immediate release tablet, Teva, 12.5 mg, bottle, 100 count, NDC 00555-0776-02
    • Amphetamine mixed salts immediate release tablet, Teva, 30 mg, bottle, 100 count, NDC 00555-0974-02
    • Amphetamine mixed salts immediate release tablet, Teva, 5 mg, bottle, 100 count, NDC 00555-0971-02
    • Amphetamine mixed salts immediate release tablet, Zydus, 12.5 mg, bottle, 100 count, NDC 68382-0953-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 15 mg, bottle, 100 count, NDC 68382-0954-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 20 mg, bottle, 100 count, NDC 68382-0955-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 30 mg, bottle, 100 count, NDC 68382-0956-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 5 mg, bottle, 100 count, NDC 68382-0950-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 7.5 mg, bottle, 100 count, NDC 68382-0951-01

Estimated Resupply Dates

    • Mallinckrodt has amphetamine mixed salts 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg immediate release tablets on allocation and the company is releasing product as it becomes available.
    • Sun Pharma has discontinued all amphetamine mixed salts, immediate-release tablets.
    • Teva has amphetamine mixed salts 7.5 mg and 10 mg tablets on back order and the company estimates a release date of early-November 2019. Amphetamine mixed salts 15 mg and 20 mg tablets are on back order and the company estimates a release date of late-October 2019.
    • Mylan has amphetamine mixed salts 5 mg, 7.5 mg, 10 mg, 12.5mg, 15 mg, 20 mg, and 30 mg immediate release tablets on back order and the company estimates a release date of late-January 2020.

Updated

Updated October 16, 2019 by Megan Dryer, PharmD. Created February 20, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins